BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Alexopoulou A, Vasilieva L, Karayiannis P. New Approaches to the Treatment of Chronic Hepatitis B. J Clin Med 2020;9:E3187. [PMID: 33019573 DOI: 10.3390/jcm9103187] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Zheng B, Yu Y, Pan Z, Feng Y, Zhao H, Han Q, Zhang J. HBsAg Dampened STING Associated Activation of NK Cells in HBeAg-Negative CHB Patients. Int J Mol Sci 2021;22:7643. [PMID: 34299262 DOI: 10.3390/ijms22147643] [Reference Citation Analysis]
2 Cargill T, Barnes E. Therapeutic vaccination for treatment of chronic hepatitis B. Clin Exp Immunol 2021;205:106-18. [PMID: 33969474 DOI: 10.1111/cei.13614] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Mahmoud RH, Hefzy EM, Shaker OG, Ahmed TI, Abdelghaffar NK, Hassan EA, Ibrahim AA, Ali DY, Mohamed MM, Abdelaleem OO. GAS5 rs2067079 and miR-137 rs1625579 functional SNPs and risk of chronic hepatitis B virus infection among Egyptian patients. Sci Rep 2021;11:20014. [PMID: 34625583 DOI: 10.1038/s41598-021-99345-2] [Reference Citation Analysis]
4 Bartoli A, Gabrielli F, Tassi A, Cursaro C, Pinelli A, Andreone P. Treatments for HBV: A Glimpse into the Future. Viruses 2021;13:1767. [PMID: 34578347 DOI: 10.3390/v13091767] [Reference Citation Analysis]
5 Wang Y, Wang Z, Liu J, Wang Y, Wu R, Sheng R, Hou T. Discovery of novel HBV capsid assembly modulators by structure-based virtual screening and bioassays. Bioorg Med Chem 2021;36:116096. [PMID: 33721800 DOI: 10.1016/j.bmc.2021.116096] [Reference Citation Analysis]
6 Ge FL, Si LL, Yang Y, Li YH, Lv ZL, Liu WH, Liao H, Wang J, Zou J, Li L, Li H, Zhang ZL, Wang JB, Lu XC, Xu DP, Bai ZF, Liu Y, Xiao XH. Chinese Patent Medicine Liuweiwuling Tablet had Potent Inhibitory Effects on Both Wild-Type and Entecavir-Resistant Hepatitis B Virus (HBV) in vitro and Effectively Suppressed HBV Replication in Mouse Model. Front Pharmacol 2021;12:756975. [PMID: 34776974 DOI: 10.3389/fphar.2021.756975] [Reference Citation Analysis]
7 Medhat A, Arzumanyan A, Feitelson MA. Hepatitis B x antigen (HBx) is an important therapeutic target in the pathogenesis of hepatocellular carcinoma. Oncotarget 2021;12:2421-33. [PMID: 34853663 DOI: 10.18632/oncotarget.28077] [Reference Citation Analysis]
8 Akbar SMF, Al Mahtab M, Cesar Aguilar J, Uddin MH, Khan MSI, Yoshida O, Penton E, Gerardo GN, Hiasa Y. Exploring evidence-based innovative therapy for the treatment of chronic HBV infection: experimental and clinical. Exploration of Medicine. [DOI: 10.37349/emed.2021.00058] [Reference Citation Analysis]
9 Le S, Martin B, Chitnis AS, Wong RJ. Screening Practices for Latent Tuberculosis Infection in Clinical Trials Evaluating Treatments for Chronic Hepatitis B Virus Infection. J Immigrant Minority Health. [DOI: 10.1007/s10903-022-01364-2] [Reference Citation Analysis]
10 Miao J, Gao P, Li Q, He K, Zhang L, Wang J, Huang L. Advances in Nanoparticle Drug Delivery Systems for Anti-Hepatitis B Virus Therapy: A Narrative Review. Int J Mol Sci 2021;22:11227. [PMID: 34681886 DOI: 10.3390/ijms222011227] [Reference Citation Analysis]
11 Maestro S, Weber ND, Zabaleta N, Aldabe R, Gonzalez-Aseguinolaza G. Novel vectors and approaches for gene therapy in liver diseases. JHEP Rep 2021;3:100300. [PMID: 34159305 DOI: 10.1016/j.jhepr.2021.100300] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
12 Castaneda D, Gonzalez AJ, Alomari M, Tandon K, Zervos XB. From hepatitis A to E: A critical review of viral hepatitis. World J Gastroenterol 2021; 27(16): 1691-1715 [PMID: 33967551 DOI: 10.3748/wjg.v27.i16.1691] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
13 Zuccaro V, Asperges E, Colaneri M, Marvulli LN, Bruno R. HBV and HDV: New Treatments on the Horizon. J Clin Med 2021;10:4054. [PMID: 34575165 DOI: 10.3390/jcm10184054] [Reference Citation Analysis]
14 Yao J, Lin C, Jiang J, Zhang X, Li F, Liu T, Diao H. lncRNA-HEIM Facilitated Liver Fibrosis by Up-Regulating TGF-β Expression in Long-Term Outcome of Chronic Hepatitis B. Front Immunol 2021;12:666370. [PMID: 34168644 DOI: 10.3389/fimmu.2021.666370] [Reference Citation Analysis]
15 Verma HK, Prasad K, Kumar P, Lvks B. Viral hepatitis: A global burden needs future directions for the management. World J Gastroenterol 2022; 28(16): 1718-1721 [DOI: 10.3748/wjg.v28.i16.1718] [Reference Citation Analysis]
16 Philips CA, Ahamed R, Abduljaleel JK, Rajesh S, Augustine P. Critical Updates on Chronic Hepatitis B Virus Infection in 2021. Cureus 2021;13:e19152. [PMID: 34733599 DOI: 10.7759/cureus.19152] [Reference Citation Analysis]
17 Huang Y, Qin A, Tsai C, Chen P. Novel Pegylated Interferon for the Treatment of Chronic Viral Hepatitis. Viruses 2022;14:1128. [DOI: 10.3390/v14061128] [Reference Citation Analysis]
18 Diogo Dias J, Sarica N, Neuveut C. Early Steps of Hepatitis B Life Cycle: From Capsid Nuclear Import to cccDNA Formation. Viruses 2021;13:757. [PMID: 33925977 DOI: 10.3390/v13050757] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Leoni S, Casabianca A, Biagioni B, Serio I. Viral hepatitis: Innovations and expectations. World J Gastroenterol 2022; 28(5): 517-531 [DOI: 10.3748/wjg.v28.i5.517] [Reference Citation Analysis]
20 Li S, Li N, Yang S, Deng H, Li Y, Wang Y, Yang J, Lv J, Dong L, Yu G, Hou X, Wang G. The study of immune checkpoint inhibitors in chronic hepatitis B virus infection. International Immunopharmacology 2022;109:108842. [DOI: 10.1016/j.intimp.2022.108842] [Reference Citation Analysis]
21 Yan Y, Qiu Y, Davgadorj C, Zheng C. Novel Molecular Therapeutics Targeting Signaling Pathway to Control Hepatitis B Viral Infection. Front Cell Infect Microbiol 2022;12:847539. [DOI: 10.3389/fcimb.2022.847539] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]